As a research hotspot in cancer immunotherapy, the cGAS‐STING pathway has been extensively reviewed, focusing on its biological mechanisms, types of modulators, and the design of nano‐DDSs for STING agonists in cancer therapy.[4, 9, 16] However, the rationale and applications of STING agonist‐based nanotherapeutics in combination with other cancer therapies remain underexplored. The gene discussed is CGAS; the disease is cancer.